Skip to content
Opens in a new window
Oral PCSK9 Inhibitor, Role of Neurology Department Chairs, Anti-IgLON5 Disease
17 September 2026

Oral PCSK9 Inhibitor, Role of Neurology Department Chairs, Anti-IgLON5 Disease

Neurology Today in 5

About

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the first oral PCSK9 inhibitor, the transforming role of the neurology department chair, and anti-IgLON5 disease.